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97(Boston Scientiﬁc, Natick, Massachusetts) was not inferior
to warfarin treatment in patients with nonvalvular atrial
ﬁbrillation (NVAF) and no contraindications to anti-
coagulation. However, published results of LAAC in
patients with contraindications to anticoagulation have
mainly been limited to small series of patients using the
PLAATO (Percutaneous Left Atrial Appendage Trans-
catheter Occlusion) device (ev3 Inc., Plymouth, Minnesota),
which is no longer available (4–8).
The AMPLATZER Cardiac Plug (ACP) device (St.
Jude Medical, Minneapolis, Minnesota) consists of a self-
expandable device with a distal lobe and proximal disk
connected by an articulating waist (Figs. 1 and 2). Two
recent studies reported the feasibility of LAAC with the
ACP device in patients with NVAF and contraindicationsFigure 2 Fluoroscopic Image of the AMPLATZER Cardiac Plug Devic
Fluoroscopic image of the AMPLATZER Cardiac Plug device after successful left atrial app
(black arrows).to anticoagulation therapy (9,10),
but no data exist on the out-
comes of such patients beyond
1-year follow-up. The objective
of this study was therefore to
evaluate the results associated
with LAAC using the ACP
device at a follow-up of 1 year
in patients with NVAF and
contraindications to anticoagu-
lation therapy.Methods
The study included a total of
52 consecutive patients with
NVAF, contraindications to anticoagulation therapy, and an
estimated risk of annual stroke of 2%, as determined by
a CHADS2 score1 (11) or CHA2DS2-VASc score2 (12)
underwentLAACwith theACPdevice at 7Canadian centers.
Device and procedure. The ACP device characteristics
andLAACprocedure were previously described in detail (13).
Transthoracic echocardiography was performed 24 h after the
procedure in all patients.
Procedural success was deﬁned as successful implantation
of the ACP device in the left atrial appendage (LAA) with
no severe residual leak. Major adverse events (MAEs) at
the index hospitalization and during the follow-up period
were deﬁned according to the Valve Academic Research
Consortium criteria (14) and included cardiovascular death, de-
vice embolization, stroke, systemic embolism, myocardial
infarction, cardiac tamponade, major bleeding, and the need for
cardiovascular surgery.
Antithrombotic therapy. Heparin (100 U/kg) was admin-
istered during the procedure in all cases, and the ﬁnal dosee
endage closure. Note the compression of the lobe by the left atrial appendage wall
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98was adjusted to achieve an activated clotting time >250 s. No
anticoagulation therapy was administered after the procedure.
Antiplatelet therapy consisting of aspirin (80 to 325 mg/24 h)
plus clopidogrel (75 mg/24 h), or aspirin or clopidogrel
alone was given according to the operators’ discretion for
30 to 180 days after the procedure, after which single-
antiplatelet therapy was given.
Follow-up. Follow-up was performed by clinical visits or
phone contact at 1, 6, and 12 months and yearly there-
after. Transesophageal echocardiography (TEE) was per-
formed in 37 patients (74% of the patients at risk) at the
6-month follow-up. The presence of device thrombosis
and residual intra- or peridevice leak were evaluated.
Residual leak was deﬁned as mild if intra- or peridevice
ﬂow was observed with a jet width 1 and <3 mm and
severe if 3 mm (15).
Statistical analysis. Continuous variables are expressed as
mean  SD or median (25th to 75th percentiles) depending
on distribution of the data. Categorical variables were
compared using a chi-square test or Fisher exact test, and
numerical variables using the Student t test or WilcoxonTable 1
Baseline Characteristics of the Study Population
(N ¼ 52)
Age, yrs 74  8
Female 22 (42.3)
Body mass index, kg/m2 27 (24–30)
Atrial ﬁbrillation type
Chronic 25 (48.1)
Paroxysmal 27 (51.9)
Hypertension 48 (92.3)
Diabetes mellitus 21 (40.4)
Thromboembolic events
Stroke 29 (55.8)
Transient ischemic attack 3 (5.8)
Coronary artery disease 26 (50.0)
Peripheral vascular disease 6 (11.5)
Previous heart failure 10 (19.2)
Previous bioprosthesis 3 (5.8)
eGFR, ml/min 72.2 (51.1–81.5)
Previous bleeding 47 (90.4)
No. of bleeding episodes 1 (1–2)
Previous liver disease 2 (3.8)
INR lability 4 (7.7)
CHADS2 score 3 (2–4)
CHA2DS2-VASc score 5 (4–6)
HAS-BLED score 4 (3–4)
Baseline antithrombotic treatment
None 10 (19.2)
Aspirin 24 (46.2)
Clopidogrel 3 (5.8)
Aspirin þ clopidogrel 15 (28.8)
Warfarin 2 (3.8)
Other anticoagulant 0
LVEF, % 60 (50–60)
LVEF 40% 8 (15.3)
Values are mean  SD, n (%), or median (25th to 75th percentiles).
INR ¼ international normalized ratio; LVEF ¼ left ventricular ejection fraction.rank sum test. Comparisons between observed and expected
rates of thromboembolic and bleeding events were assessed
using binomial tests. Kaplan-Meier curves were used to
analyze cumulative outcomes at 2-year follow-up. All anal-
yses were conducted using the SAS statistical package
version 9.2 (SAS Institute Inc., Cary, North Carolina).
Results
Baseline characteristics and procedural ﬁndings of the study
population are shown in Table 1. Reasons for anti-
coagulation therapy contraindications are shown in Table 2.
Procedural results and in-hospital outcomes. The main
procedural ﬁndings and acute results are shown in Table 3.
The procedure was successful in all patients but 1 (98.1%).
One patient had a device embolization a few minutes after
implantation, most likely related to device undersizing. The
device was successfully retrieved percutaneously with no
complications.
During the hospitalization period, there were no deaths or
strokes. One patient had a transient ischemic attack (TIA)
24 h after the procedure while on aspirin plus clopidogrel
therapy. TEE showed the absence of intracardiac thrombi
and complete LAA sealing.
Follow-up. The mean follow-up was 20  5 months
(12 months in all patients). The late clinical outcomes are
shown in Table 4. A total of 3 patients (5.8%) died during the
follow-up period, and no death was related to the device. One
patient had a lacunar stroke 16 months after the procedure,
with complete recovery and no sequelae. The patient was
receiving clopidogrel at the time of the event. Another patient
had a TIA at the 6-month follow-up while on aspirin plus
clopidogrel therapy. TEE showed the absence of cardiac
thrombi and complete LAA sealing. One patient had
a cardiac tamponade requiring pericardiocentesis 1 month
after the procedure without evidence of perforation by TEE
and computed tomography. Another patient experienced
major bleeding related to angiodysplasia. The main clinical
characteristics of patients with MAEs during the follow-upTable 2
Reasons for Anticoagulation Therapy Contraindication
(N ¼ 52)
Bleeding
Intracranial hemorrhage 18 (34.6)
Gastrointestinal bleeding 12 (23.1)
Spontaneous hematoma of abdominal muscles 7 (13.5)
Otorhinolaryngological 4 (7.7)
Respiratory 3 (5.8)
Recurrent severe hematuria 1 (1.9)
Ophthalmological 1 (1.9)
Recurrent hemarthrosis 1 (1.9)
International normalized ratio lability 2 (3.8)
High risk of fall 1 (1.9)
Warfarin allergy 1 (1.9)
Severe anemia 1 (1.9)
Values are n (%).
Table 4 Follow-Up Results
Median of follow-up, months 20  5
Antithrombotic therapy at last follow-up
Aspirin 32 (61.5)
Clopidogrel 6 (11.5)
Aspirin þ clopidogrel 9 (17.3)
None 5 (9.6)
Device embolization 0 (0)
Cardiac tamponade 1 (1.9)
Major bleeding 1 (1.9)
Transient ischemic attack 1 (1.9)
Stroke 1 (1.9)
Systemic embolism 0 (0)
Death
Overall 3 (5.8)
Cardiovascular or neurologic death* 1 (1.9)
Values are mean  SD or n (%). *Patient died of heart failure.
Table 3 Procedural and In-Hospital Findings
Procedural ﬁndings
LAA diameter by TEE at 45 , mm 18  4
LAA diameter by TEE at 120 , mm 20  4
LAA diameter by angiography, mm 20  3
Device size, mm
18 1 (1.9)
20 9 (17.3)
22 16 (30.8)
24 11 (21.2)
26 8 (15.4)
28 4 (7.7)
30 3 (5.8)
Ratio device/LAA ostium* 1.16  0.11
Procedural success 51 (98.1)
In-hospital outcomes
Pericardial effusion 0 (0)
Major bleedingy 2 (3.8)
Device embolization 1 (1.9)
Myocardial infarction 0 (0)
Systemic embolism 0 (0)
Transient ischemic attack 1 (1.9)
Stroke 0 (0)
Death 0 (0)
MAEsz 3 (5.8)
Hospitalization length, days 1 (1–1)
Values are mean  SD, n (%), or median (25th to 75th percentiles). *As measured by angiography.
yDue to access site hematoma in all cases. zIncluded cardiovascular death, device embolization,
stroke, systemic embolism, myocardial infarction, cardiac tamponade, major bleeding, and need
for cardiovascular surgery.
LAA ¼ left atrial appendage; MAEs ¼ major adverse event(s); TEE ¼ transesophageal
echocardiography.
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99period are shown in Table 5. The rates of cumulative observed
versus expected MAEs are shown in Figure 3. The Kaplan-
Meier survival curves are shown in Figure 4.
Echocardiography data. Immediately after the procedure,
a mild intradevice and peridevice leak were observed in 1
(1.9%) and 6 (11.5%) patients, respectively, and all but 1
leak had disappeared on TEE performed at the 6-month
follow-up. A total of 5 patients with no leak immediately
after the procedure had a mild peridevice leak as deter-
mined by TEE at the 6-month follow-up resulting in
a global incidence of peridevice leaks at follow-up ofTable 5 Individual Characteristics of Patients With Major Adverse Ev
Age, yrs
CHADS2
Score
CHA2DS2-VASc
Score
HAS-BLED
Score
Prosthesis
Size, mm
Perid
Le
67 4 7 5 22 Mild
69 2 3 2 26 No
73 2 4 2 18 No
78 5 8 5 22 No
80 4 7 5 24 No
81 3 4 4 28 Unkn
*Patient died of heart failure.
CVD ¼ cardiovascular death; MAEs ¼ major adverse event(s); TIA ¼ transient ischemic attack; other16.2%. A lower left ventricular ejection fraction was asso-
ciated with the occurrence of a new peridevice leak at the
6-month follow-up (p ¼ 0.016) (Table 6). None of the
patients with residual leaks had a cardioembolic event.
There were no cases of device thrombosis or late device
embolization.
Discussion
LAAC with the ACP device: acute results. LAAC with
the ACP device was associated with a high rate of procedural
success (98.1%) and low rate of periprocedural complications
(device embolization, 1.9%; TIA, 1.9%; pericardial effusion,
1.9%). These results compared with those of previous
studies on LAAC in patients with contraindications to
anticoagulation therapy are shown in Table 7.
Follow-up. This study showed that a strategy of LAAC
followed by antiplatelet therapy was associated with a low
rate of embolic events (stroke, 1.9%; systemic embolism,
0%) at a mean follow-up of 20 months, lower than the event
rate expected on the basis of the characteristics of the study
population (Fig. 3). Of note, avoiding a short-term period
of anticoagulation after LAAC was not associated with any
embolic event or device thrombosis, suggesting that the useents at Follow-Up
evice
ak Antithrombotic Therapy MAEs Timing, months
Aspirin Major bleeding 1
Aspirin þ clopidogrel TIA 5
Aspirin þ clopidogrel Cardiac tamponade 1
Aspirin CVD* 8
Aspirin Non-CVD 3
own Clopidogrel Stroke 16
Clopidogrel Non-CVD 22
abbreviations as in Table 3.
Figure 3
Expected Versus Observed Thromboembolic and
Bleeding Events
Expected annual rates of stroke and thromboembolic (stroke, TIA, systemic
embolism) and bleeding events in the study population based on CHADS2 (11),
CHA2DS2-VASc (21) and HAS-BLED (22) scores, respectively, compared with the
cumulative observed rates during the entire study period. The observed annual
rates of stroke and thromboembolic and bleeding events were 87%, 66%, and
61%, respectively, lower than expected. However, actual observed event rates with
anticoagulation therapy were lower than expected in the PROTECT AF trial (3), the
only randomized trial comparing anticoagulation and left atrial appendage closure,
and, thus, real rates of stroke and thromboembolic and bleeding events in this
population in the absence of left atrial appendage closure might differ from these
estimates. These results will have to be conﬁrmed by randomized trials. *Included
patients to whom aspirin had been prescribed. yPatients on aspirin were included.
TIA ¼ transient ischemic attack.
Figure 4
Survival Curves After Percutaneous Left Atrial
Appendage Closure With the AMPLATZER
Cardiac Plug Device
Kaplan-Meier survival curves at 2-year follow-up showing the percentage of
patients free of death, stroke, and major bleeding.
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100of percutaneous LAAC may be a therapeutic alternative
to avoid thromboembolic events in patients with absolute
contraindications to anticoagulation therapy. Also, the use
of single-antiplatelet therapy was associated with a lower-
than-expected rate of bleeding, with only 1 seriousTable 6
Echocardiographic Findings According t
New Peridevice Leaks at 6-Month Follow
Overall
(N ¼ 37)
Paroxysmal AF 18 (58.6)
LA diameter, mm 45  11
LA volume, mm3/cm2 38  14
LAA ostium width by TEE at 45 , mm 18  3
LAA ostium width by TEE at 120, mm 20  3
LAA ostium width by angiography, mm 20  3
Device size, mm 22 (22–26)
18–20 6 (16.2)
22 14 (37.8)
24 8 (21.6)
26 7 (18.9)
28–30 2 (5.4)
Ratio device/LAA ostium* 1.16  0.13
LVEF, % 60 (50–60)
Values are n (%), mean  SD, or median (25th to 75th percentiles). *As m
AF ¼ atrial ﬁbrillation; LA ¼ left atrium; LVEF ¼ left ventricular ejectionhemorrhagic event occurring during the follow-up period
(1.9%) (Fig. 3). However, 2 cases of asymptomatic ACP
device thrombosis were previously reported at 3 and 6
months after LAAC in patients on single-antiplatelet
treatment (16), highlighting the need for larger studies to
further evaluate the incidence and clinical relevance of
device thrombosis in such patients.
Data on LAAC in patients with contraindications to
anticoagulation therapy have been limited to a few series of
patients who had undergone LAAC with the PLAATO
device (4–8), no longer available, the recently presented
ASAP (ASA Plavix Feasibility Study with Watchmano the Presence of
-Up
Peridevice Leak
(n ¼ 5)
No Peridevice Leak
(n ¼ 32) p Value
4 (80.0) 14 (43.8) 0.180
48  9 43  13 0.475
38  10 37  17 0.943
17  2 19  3 0.184
18  2 20  3 0.290
21  3 20  3 0.654
22 (22–24) 22 (22–26) 0.758
0 6 (18.8)
3 (60.0) 11 (34.4)
2 (40.0) 6 (18.8) 0.548
0 7 (21.9)
0 2 (6.3)
1.12  0.16 1.17  0.13 0.390
37 (27–52) 60 (50–60) 0.016
easured by angiography.
fraction; other abbreviations as in Table 3.
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101Left Atrial Appendage Closure Technology) (17) and the
limited experience with the LARIAT device (18). Con-
sistent with the results of the present study, LAAC fol-
lowed by antiplatelet therapy was associated with a low
rate of cerebrovascular events at follow-up (Table 7).
Residual leaks. Mild residual leaks after percutaneous
LAAC have been reported in as many as 32% and 75% of
the patients after WATCHMAN and PLAATO device
implantation, respectively (15,19). The low rate of residual
leak observed in this study (16.2%) may be related to the
double-disk structure of the ACP device with a larger
proximal disk that covers the LAA oriﬁce from the left
atrium side, contributing to a better sealing of the LAA. Of
note, in as many as 5 patients (13.5%) with no leak
immediately after the procedure, a new peridevice leak
developed over time. This was previously reported using the
WATCHMAN device (20) and might be related to
incomplete device endothelialization or some degree of
device undersizing without periprocedural residual leak due
to LAA contraction immediately after the implantation.
Also, the fact that a low left ventricular ejection fraction
was associated with a peridevice leak suggests that changes
in the left atrial dimensions over time might play a role in
the occurrence of these late leaks. Importantly, the presence
of mild residual leaks was not associated with any car-
dioembolic event, and this was consistent with the results
of previous studies (15).
Study limitations. Although this is the study with the
longest follow-up in patients undergoing LAAC with the
ACP device to date, the sample size was limited. The rate
of expected events was based on historical controls, which
have not been validated in the present population. The
possibility of a type I error cannot be ruled out. These
results will therefore have to be conﬁrmed by randomized,
controlled trials. TEE examinations at follow-up were in-
complete, not analyzed in an echocardiography core labo-
ratory, and only performed once, which may have limited
the possibility of thrombus device detection. Finally,
although clinical data were prospectively collected at each
center, no pre-speciﬁed case report form or event adjudi-
cation committee was used.
Conclusions
In patients with NVAF at high risk of cardioembolic events
and with contraindications to anticoagulation therapy,
percutaneous LAAC with the ACP device followed by
dual-/single-antiplatelet therapy was associated with a low
rate of cardioembolic and bleeding complications at a mean
follow-up of 20 months. LAAC was successful in >98% of
patients, with a small proportion having mild residual leak,
and no cases of severe residual leak or device thrombosis
were observed. However, these results do not provide
sufﬁcient evidence to state that LAAC without anti-
coagulation provides sufﬁcient safety to recommend this
approach until adequate data from clinical trials can be
Urena et al. JACC Vol. 62, No. 2, 2013
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102obtained. Also, larger studies with a longer follow-up and
a more complete echocardiographic follow-up will have to
conﬁrm these results.
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